SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Drostanolone propionate | Drostanolone enanthate | Stanolone / Dihydrotestosterone |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Injectable anabolic-androgenic steroid with historical oncology use | Unapproved long-ester anabolic steroid | Endogenous androgen and non-aromatisable androgen medicine in limited jurisdictions |
| PrimeCore Class | Class BInvestigational | Class BInvestigational | Class BInvestigational |
| Evidence Grade | Grade DLimited / observational evidence | Grade EPreclinical evidence | Grade DLimited / observational evidence |
| Evidence boundary | Drostanolone propionate is classified here as Injectable anabolic-androgenic steroid with historical oncology use. Historical breast-cancer use does not establish modern performance benefit or product safety. No current FDA-approved product was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Drostanolone enanthate is classified here as Unapproved long-ester anabolic steroid. No adequate authorised human product or therapeutic trial programme was identified. No FDA-approved human medicine was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Stanolone / Dihydrotestosterone is classified here as Endogenous androgen and non-aromatisable androgen medicine in limited jurisdictions. Endogenous biology and country-specific products do not authenticate supplier injections or establish performance benefit. No current FDA-approved injectable stanolone product was identified; prohibited by WADA at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions